Neutralization Takes Precedence Over IgG or IgA Isotype-related Functions in Mucosal HIV-1 Antibody-mediated Protection.

Journal Article (Journal Article)

HIV-1 infection occurs primarily through mucosal transmission. Application of biologically relevant mucosal models can advance understanding of the functional properties of antibodies that mediate HIV protection, thereby guiding antibody-based vaccine development. Here, we employed a human ex vivo vaginal HIV-1 infection model and a rhesus macaque in vivo intrarectal SHIV challenge model to probe the protective capacity of monoclonal broadly-neutralizing (bnAb) and non-neutralizing Abs (nnAbs) that were functionally modified by isotype switching. For human vaginal explants, we developed a replication-competent, secreted NanoLuc reporter virus system and showed that CD4 binding site bnAbs b12 IgG1 and CH31 IgG1 and IgA2 isoforms potently blocked HIV-1JR-CSF and HIV-1Bal26 infection. However, IgG1 and IgA nnAbs, either alone or together, did not inhibit infection despite the presence of FcR-expressing effector cells in the tissue. In macaques, the CH31 IgG1 and IgA2 isoforms infused before high-dose SHIV challenge were completely to partially protective, respectively, while nnAbs (CH54 IgG1 and CH38 mIgA2) were non-protective. Importantly, in both mucosal models IgG1 isotype bnAbs were more protective than the IgA2 isotypes, attributable in part to greater neutralization activity of the IgG1 variants. These findings underscore the importance of potent bnAb induction as a primary goal of HIV-1 vaccine development.

Full Text

Duke Authors

Cited Authors

  • Astronomo, RD; Santra, S; Ballweber-Fleming, L; Westerberg, KG; Mach, L; Hensley-McBain, T; Sutherland, L; Mildenberg, B; Morton, G; Yates, NL; Mize, GJ; Pollara, J; Hladik, F; Ochsenbauer, C; Denny, TN; Warrier, R; Rerks-Ngarm, S; Pitisuttithum, P; Nitayapan, S; Kaewkungwal, J; Ferrari, G; Shaw, GM; Xia, S-M; Liao, H-X; Montefiori, DC; Tomaras, GD; Haynes, BF; McElrath, JM

Published Date

  • December 2016

Published In

Volume / Issue

  • 14 /

Start / End Page

  • 97 - 111

PubMed ID

  • 27919754

Pubmed Central ID

  • PMC5161443

Electronic International Standard Serial Number (EISSN)

  • 2352-3964

International Standard Serial Number (ISSN)

  • 2352-3964

Digital Object Identifier (DOI)

  • 10.1016/j.ebiom.2016.11.024


  • eng